Eisai publish series of BK Channel-Opening Agents

Eisai have published a series of Oxime and Oxime Ether 12,14-Dichlorodehydroabietic Acid derivative BK Channel-Opening Agents

NeurogesX Submit NDA for NGX-4010 for Treatment of Postherpetic Neuralgia (PHN)

NeurogesX have submitted a new drug application (NDA) with the U.S. FDAS for NGX-4010 Dermal Capsaicin Patch for the management of pain due to postherpetic neuralgia (PHN).

Merck publish series of T-Type Calcium Channel blockers

Merck have published a series of  T-Type Calcium Channel blockers

Cellectricon to incorporate Tecella’s Richmond patch clamp amplifier in next generation Dynaflow HT platform

Cellectricon have announced that they will be incorporating Tecella’s Richmond patch clamp amplifier in next generation Dynaflow HT platform

AstraZeneca and Cellectricon collaborate on Dynaflow High Throughput Ion Channel Screening

AstraZeneca have expanded their collaboration with Cellectricon. AstraZeneca will install two Dynaflow high throughput ion channel screening systems.

Pierre Fabre describe new sodium channel NaV1.5 Blockers

Researchers at Pierre Fabre have described a series of cardiac sodium channel NaV1.5. blockers. One compound of the series was found to be more potent than KC 12291, ranolazine, and ivabradine in a rabbit model of ischemia−reperfusion.

NHE-1 inhibitors shift Sodium channels into the inactive state

Pfizer scientists report that NHE-1 inhibitors may to reduce peripheral neuronal excitability by shifting fast Na+ channels into the inactivated state.